The global anti-snoring treatment market size reached USD 1.7 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 3.4 Billion by 2033, exhibiting a growth rate (CAGR) of 7.54% during 2025-2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 1.7 Billion |
Market Forecast in 2033
|
USD 3.4 Billion |
Market Growth Rate (2025-2033) | 7.54% |
Snoring refers to a noisy breathing sound coming through the nose or mouth of an individual, which is caused by the vibration of the soft tissues of the throat. It is medically treated using surgery or continuous positive airway pressure (CPAP), wherein a mask is worn over the nose or mouth and attached to a machine for delivering a constant flow of air into the nostrils. It can also be cured via lifestyle changes, such as maintaining body weight, relieving the nasal obstruction, changing sleep positions, and avoiding alcohol and sedating medications.
Rising technological advancements in devices that support anti-snoring treatment represent one of the key factors positively influencing the market. Moreover, long-term snoring increases the risk of developing fatigue, heart attacks, hypertension, stroke, type 2 diabetes, and decreased blood oxygen levels. Besides this, loud and frequent snoring is one of the signs of sleep apnea, which is a chronic condition characterized by shallow breaths or pauses in breathing during sleep. This condition can lead to glaucoma, cancer, and cognitive and behavioral disorders. In addition, people with sleep apnea have an increased threat of motor vehicle accidents as it can affect driving fitness. Consequently, there is a rise in the usage of anti-snoring apps, behavioral therapies, dental devices, tongue stabilizing devices (TSD), and mandibular advancing devices (MAD), also known as jaw advancing devices (JAD), to treat snoring, which is fueling the market growth. Furthermore, factors like sedentary lifestyles, unhealthy dietary habits, increasing tobacco and alcohol consumption, and the rising prevalence of sleep disorders among the masses are projected to create a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global anti-snoring treatment market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on device type and distribution channel.
Breakup by Device Type:
Breakup by Distribution Channel:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Airway Management Inc., Apnea Sciences Corporation, Fisher & Paykel Healthcare Corporation Limited, Koninklijke Philips N.V., MEDiTAS Ltd., Medtronic plc, Mitsui Chemicals Inc., ResMed Inc., Rotech Healthcare Inc., SomnoMed, The Pure Sleep Company and Tomed GmbH.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Device Type, Distribution Channel, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Airway Management Inc., Apnea Sciences Corporation, Fisher & Paykel Healthcare Corporation Limited, Koninklijke Philips N.V., MEDiTAS Ltd., Medtronic plc, Mitsui Chemicals Inc., ResMed Inc., Rotech Healthcare Inc., SomnoMed, The Pure Sleep Company and Tomed GmbH. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global anti-snoring treatment market was valued at USD 1.7 Billion in 2024.
We expect the global anti-snoring treatment market to exhibit a CAGR of 7.54% during 2025-2033.
The rising prevalence of sleep disorders, along with the increasing adoption of various lifestyle changes, such as maintaining body weight, relieving the nasal obstruction, changing sleep positions, etc., is primarily driving the global anti-snoring treatment market.
The sudden outbreak of the COVID-19 pandemic had led to the postponement of elective anti-snoring treatment procedures to reduce the risk of the coronavirus infection upon hospital visits and interaction with healthcare professionals or medical equipment.
Based on the device type, the global anti-snoring treatment market has been segregated into Mandibular Advancement Devices (MAD), Tongue Stabilizing Devices (TSD), Continuous Positive Airway Pressure (CPAP) devices, and others. Among these, Continuous Positive Airway Pressure (CPAP) devices currently hold the largest market share.
Based on the distribution channel, the global anti-snoring treatment market can be bifurcated into hospital pharmacies, retail pharmacies, online, and others. Currently, hospital pharmacies exhibit a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global anti-snoring treatment market include Airway Management Inc., Apnea Sciences Corporation, Fisher & Paykel Healthcare Corporation Limited, Koninklijke Philips N.V., MEDiTAS Ltd., Medtronic plc, Mitsui Chemicals Inc., ResMed Inc., Rotech Healthcare Inc., SomnoMed, The Pure Sleep Company, and Tomed GmbH.